145 related articles for article (PubMed ID: 20436376)
1. A single-nucleotide polymorphism of alanine to threonine at position 163 of the human angiotensin II type 1 receptor impairs Losartan affinity.
Arsenault J; Lehoux J; Lanthier L; Cabana J; Guillemette G; Lavigne P; Leduc R; Escher E
Pharmacogenet Genomics; 2010 Jun; 20(6):377-88. PubMed ID: 20436376
[TBL] [Abstract][Full Text] [Related]
2. Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation.
Montón M; Jiménez A; Núñez A; López-Blaya A; Farré J; Gómez J; Zalba LR; Sánchez de Miguel L; Casado S; López-Farré A
J Cardiovasc Pharmacol; 2000 Jun; 35(6):906-13. PubMed ID: 10836725
[TBL] [Abstract][Full Text] [Related]
3. The pharmacological potency of various AT(1) antagonists assessed by Schild regression technique in man.
Belz GG; Breithaupt-Grögler K; Butzer R; Fuchs W; Hausdorf C; Mang C
J Renin Angiotensin Aldosterone Syst; 2000 Dec; 1(4):336-41. PubMed ID: 11967820
[TBL] [Abstract][Full Text] [Related]
4. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing.
Maillard MP; Würzner G; Nussberger J; Centeno C; Burnier M; Brunner HR
Clin Pharmacol Ther; 2002 Jan; 71(1):68-76. PubMed ID: 11823759
[TBL] [Abstract][Full Text] [Related]
5. Internalization of constitutively active N111G MUTANT of AT1 receptor induced by angiotensin II-receptor antagonists candesartan, losartan, and telmisartan: comparison with valsartan.
Bhuiyan MA; Hossain M; Nakamura T; Ozaki M; Nagatomo T
J Pharmacol Sci; 2010; 112(4):459-62. PubMed ID: 20308802
[TBL] [Abstract][Full Text] [Related]
6. Interaction between the partially insurmountable antagonist valsartan and human recombinant angiotensin II type 1 receptors.
Verheijen I; Fierens FL; Debacker JP; Vauquelin G; Vanderheyden PM
Fundam Clin Pharmacol; 2000; 14(6):577-85. PubMed ID: 11206708
[TBL] [Abstract][Full Text] [Related]
7. A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists.
Vauquelin G; Morsing P; Fierens FL; De Backer JP; Vanderheyden PM
Biochem Pharmacol; 2001 Feb; 61(3):277-84. PubMed ID: 11172731
[TBL] [Abstract][Full Text] [Related]
8. Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay.
Belz GG; Butzer R; Kober S; Mang C; Mutschler E
Clin Pharmacol Ther; 1999 Oct; 66(4):367-73. PubMed ID: 10546920
[TBL] [Abstract][Full Text] [Related]
9. Binding of valsartan to mammalian angiotensin AT1 receptors.
de Gasparo M; Whitebread S
Regul Pept; 1995 Nov; 59(3):303-11. PubMed ID: 8577935
[TBL] [Abstract][Full Text] [Related]
10. Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors.
Vanderheyden PM; Fierens FL; De Backer JP; Fraeyman N; Vauquelin G
Br J Pharmacol; 1999 Feb; 126(4):1057-65. PubMed ID: 10193788
[TBL] [Abstract][Full Text] [Related]
11. Reversible and syntopic interaction between angiotensin receptor antagonists on Chinese hamster ovary cells expressing human angiotensin II type 1 receptors.
Vanderheyden PM; Fierens FL; De Backer J; Vauquelin G
Biochem Pharmacol; 2000 Apr; 59(8):927-35. PubMed ID: 10692557
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists.
Mazzolai L; Maillard M; Rossat J; Nussberger J; Brunner HR; Burnier M
Hypertension; 1999 Mar; 33(3):850-5. PubMed ID: 10082498
[TBL] [Abstract][Full Text] [Related]
13. Insurmountable angiotensin AT1 receptor antagonists: the role of tight antagonist binding.
Fierens FL; Vanderheyden PM; De Backer JP; Vauquelin G
Eur J Pharmacol; 1999 May; 372(2):199-206. PubMed ID: 10395100
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin II type 1 receptor blockers.
Burnier M
Circulation; 2001 Feb; 103(6):904-12. PubMed ID: 11171802
[No Abstract] [Full Text] [Related]
15. Functional comparison of the antagonistic properties of some Angiotensin II type 1 receptor blockers on the contraction elicited by Angiotensin II and thromboxane A2 on human saphenous veins.
Hakim A; Stanke-Labesque F; Hoffmann P; Sessa C; Caron F; Cracowski JL; Bessard G
J Cardiovasc Pharmacol; 2003 Jul; 42(1):42-7. PubMed ID: 12827025
[TBL] [Abstract][Full Text] [Related]
16. Peptide and nonpeptide antagonist interaction with constitutively active human AT1 receptors.
Le MT; Vanderheyden PM; Szaszák M; Hunyady L; Kersemans V; Vauquelin G
Biochem Pharmacol; 2003 Apr; 65(8):1329-38. PubMed ID: 12694873
[TBL] [Abstract][Full Text] [Related]
17. Assessment of angiotensin II receptor blockade in humans using a standardized angiotensin II receptor-binding assay.
Maillard MP; Mazzolai L; Daven V; Centeno C; Nussberger J; Brunner HR; Burnier M
Am J Hypertens; 1999 Dec; 12(12 Pt 1-2):1201-8. PubMed ID: 10619583
[TBL] [Abstract][Full Text] [Related]
18. Antagonist interaction with endogenous AT(1) receptors in human cell lines.
Verheijen I; Vanderheyden PM; De Backer JP; Bottari S; Vauquelin G
Biochem Pharmacol; 2002 Oct; 64(8):1207-14. PubMed ID: 12234601
[TBL] [Abstract][Full Text] [Related]
19. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent.
Wong PC; Price WA; Chiu AT; Duncia JV; Carini DJ; Wexler RR; Johnson AL; Timmermans PB
J Pharmacol Exp Ther; 1990 Oct; 255(1):211-7. PubMed ID: 2213556
[TBL] [Abstract][Full Text] [Related]
20. Comparative vascular and renal tubular effects of angiotensin II receptor blockers combined with a thiazide diuretic in humans.
Coltamai L; Maillard M; Simon A; Vogt B; Burnier M
J Hypertens; 2010 Mar; 28(3):520-6. PubMed ID: 20104189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
